None listed
Conditions
Interventions
Intervention1: 50 mcg of Dextromethorphan hydrochloride: under fasting conditions, Single Oral dose and collecting sequence of time points (8 times) and genetic variability will be assessed with drug
Sponsors
PSG Institute of Medical Sciences and Research
Eligibility
Inclusion criteria
Inclusion criteria: Above 18 years patients will be included,and who have normal result in the screening procedure. subject not on any medications which are metabolized by the CYP2D6 metabolic pathway. Female volunteers should test for negative to pregnancy test
Exclusion criteria
Exclusion criteria: Not given consent will not be included and who fail the screening procedure and not declared healthy by the physician. subject who are allergic to dextromethorphan. subjects who have a history of chronic alcoholism and habit of smoking heavily. subjects who have drugs abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic profile (NCA analysis)Timepoint: pre-dose (0.00) and at 0.50, 1.00, 2.00, 4.00, 8.00, 12.00 and 24.00 hours post dose | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacogenetic outcome measures in CYP2D6 expression in Control vs treated group. Cmax time point the outcome will be assessed with the interval of every 4 weeksTimepoint: Cmax Time point, concentration will be compared b/w the groups in the interval of every 4 weeks | — |
Countries
India
Contacts
Public ContactDr Sivaselvakumar Muthusamy
PSG Institute of Medical Sciences and Research
Outcome results
None listed